Shots:

• Roche signs a 15yrs. non-exclusive agreement with Illumina- allowing patients to access next-generation sequencing (NGS) based testing in oncology
• Roche to get right to develop & commercialize AVENIO IVD tests for both tissue and blood to be used on Illumina’s NextSeq 550Dx System while Illumina will continue to commercialize its NextSeq 550Dx Systems and core sequencing consumables
• Additionally- Roche & Illumina collaborate to develop and pursue CDx claims on TSO 500 for both existing and pipeline Roche’s oncology targeted therapies on the NextSeq 550Dx System. Illumina will be responsible for the development- regulatory & commercial activities of TSO 500 while Roche will support the development of the claims and regulatory filings

Click here ­to­ read full press release/ article 

Ref: Roche | Image: Roche